AI Summary & Key Takeaways
AI InsightOur findings showed that the chance of long-term remission increases in directproportion to the initial ATD treatment duration and the total ATD treatment duration.
📌 3 Key Takeaways
Abstract
Background/aim: Graves’ disease (GD) is more severe, requires a more complex treatment, and has a lower probability of achievingremission in children than in adults. There is no consensus on the appropriate duration of antithyroid drug (ATD) treatment. Surgicalor radioactive iodine (RAI) treatments are not definitive and generally result in permanent hypothyroidism. This study’s goal wasexamining the effectiveness of ATD treatment in children and adolescents with GD and determining the risk factors of remission andrelapse.Materials and methods: This retrospective study included 45 patients (36 females and 9 males, median age 12.5 years) aged 4–18 whowere diagnosed with GD between 2003 and 2017. All patients initially were treated with an ATD. ATD treatment was discontinued at amean of 23.2 ± 13.2 months (10–37 months).Results: Patients were classified into remission (n = 24) and relapse groups (n = 21). The duration of initial ATD treatment in theremission group was longer (26.91 ± 5.17 months) than in the relapse group (19.09 ± 7.14 months) (P = 0.01). The total ATD treatmentduration was statistically longer in the remission group (42.14 ± 14.35 months) than in the relapse group (26.95 ± 16.13 months) (P =0.03).Conclusion: Long-term initial ATD treatment and long-term total ATD treatment were evaluated as positive parameters for theremission of Graves’ disease in children and adolescents. Our findings showed that the chance of long-term remission increases in directproportion to the initial ATD treatment duration and the total ATD treatment duration.